Abstract
Impaired Neutralising Antibodies to SARS-CoV-2 Omicron BA.2 Variant and Preserved Cellular Immunogenicity Following Heterologous Prime-Boost Vaccination with an Inactivated Vaccine Followed by ChAdOx1-nCoV-19 in Patients with Systemic Autoimmune Rheumatic Diseases
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
